Salvage Therapy after Allogeneic Hematopoietic Cell Transplantation: Targeted and Low-Intensity Treatment Options in Myelodysplastic Syndrome and Acute Myeloid Leukemia
Patients with high-risk myeloid neoplasms, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), are offered allogeneic hematopoietic cell transplantation (alloHCT) to improve the likelihood of long-term disease control. More than 50% of patients with high-risk disease will rela...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAABRON PRESS
2019-05-01
|
| Series: | Clinical Hematology International |
| Subjects: | |
| Online Access: | https://www.atlantis-press.com/article/125906450/view |
| _version_ | 1797226787465330688 |
|---|---|
| author | Katie Culos Michael Byrne |
| author_facet | Katie Culos Michael Byrne |
| author_sort | Katie Culos |
| collection | DOAJ |
| description | Patients with high-risk myeloid neoplasms, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), are offered allogeneic hematopoietic cell transplantation (alloHCT) to improve the likelihood of long-term disease control. More than 50% of patients with high-risk disease will relapse after HCT and face a poor prognosis with shortened survival. The recent development of targeted therapies and effective, low-intensity treatment strategies will likely improve the outcomes of these patients. In MDS, hypomethylating agents (HMAs) are the mainstay of salvage therapy but new treatments with APR-246 and luspatercept demonstrate excellent results in phase 1 and phase 3 clinical studies, respectively. In AML, new directed agents in the relapsed/refractory setting include gilteritinib (FLT3-ITD/-TKD), ivosidenib (IDH1), and enasidenib (IDH2). In patients without targetable mutations, HMAs may be used, and early data with venetoclax-based regimens are encouraging. |
| first_indexed | 2024-04-24T14:30:27Z |
| format | Article |
| id | doaj.art-d92f5b7d96544440ae85dca55561a8e5 |
| institution | Directory Open Access Journal |
| issn | 2590-0048 |
| language | English |
| last_indexed | 2024-04-24T14:30:27Z |
| publishDate | 2019-05-01 |
| publisher | SAABRON PRESS |
| record_format | Article |
| series | Clinical Hematology International |
| spelling | doaj.art-d92f5b7d96544440ae85dca55561a8e52024-04-03T03:50:10ZengSAABRON PRESSClinical Hematology International2590-00482019-05-011210.2991/chi.d.190503.001Salvage Therapy after Allogeneic Hematopoietic Cell Transplantation: Targeted and Low-Intensity Treatment Options in Myelodysplastic Syndrome and Acute Myeloid LeukemiaKatie CulosMichael ByrnePatients with high-risk myeloid neoplasms, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), are offered allogeneic hematopoietic cell transplantation (alloHCT) to improve the likelihood of long-term disease control. More than 50% of patients with high-risk disease will relapse after HCT and face a poor prognosis with shortened survival. The recent development of targeted therapies and effective, low-intensity treatment strategies will likely improve the outcomes of these patients. In MDS, hypomethylating agents (HMAs) are the mainstay of salvage therapy but new treatments with APR-246 and luspatercept demonstrate excellent results in phase 1 and phase 3 clinical studies, respectively. In AML, new directed agents in the relapsed/refractory setting include gilteritinib (FLT3-ITD/-TKD), ivosidenib (IDH1), and enasidenib (IDH2). In patients without targetable mutations, HMAs may be used, and early data with venetoclax-based regimens are encouraging.https://www.atlantis-press.com/article/125906450/viewMyelodysplastic syndromeAcute myeloid leukemiaHematopoietic cell transplantationRelapse |
| spellingShingle | Katie Culos Michael Byrne Salvage Therapy after Allogeneic Hematopoietic Cell Transplantation: Targeted and Low-Intensity Treatment Options in Myelodysplastic Syndrome and Acute Myeloid Leukemia Clinical Hematology International Myelodysplastic syndrome Acute myeloid leukemia Hematopoietic cell transplantation Relapse |
| title | Salvage Therapy after Allogeneic Hematopoietic Cell Transplantation: Targeted and Low-Intensity Treatment Options in Myelodysplastic Syndrome and Acute Myeloid Leukemia |
| title_full | Salvage Therapy after Allogeneic Hematopoietic Cell Transplantation: Targeted and Low-Intensity Treatment Options in Myelodysplastic Syndrome and Acute Myeloid Leukemia |
| title_fullStr | Salvage Therapy after Allogeneic Hematopoietic Cell Transplantation: Targeted and Low-Intensity Treatment Options in Myelodysplastic Syndrome and Acute Myeloid Leukemia |
| title_full_unstemmed | Salvage Therapy after Allogeneic Hematopoietic Cell Transplantation: Targeted and Low-Intensity Treatment Options in Myelodysplastic Syndrome and Acute Myeloid Leukemia |
| title_short | Salvage Therapy after Allogeneic Hematopoietic Cell Transplantation: Targeted and Low-Intensity Treatment Options in Myelodysplastic Syndrome and Acute Myeloid Leukemia |
| title_sort | salvage therapy after allogeneic hematopoietic cell transplantation targeted and low intensity treatment options in myelodysplastic syndrome and acute myeloid leukemia |
| topic | Myelodysplastic syndrome Acute myeloid leukemia Hematopoietic cell transplantation Relapse |
| url | https://www.atlantis-press.com/article/125906450/view |
| work_keys_str_mv | AT katieculos salvagetherapyafterallogeneichematopoieticcelltransplantationtargetedandlowintensitytreatmentoptionsinmyelodysplasticsyndromeandacutemyeloidleukemia AT michaelbyrne salvagetherapyafterallogeneichematopoieticcelltransplantationtargetedandlowintensitytreatmentoptionsinmyelodysplasticsyndromeandacutemyeloidleukemia |